150 related articles for article (PubMed ID: 29512735)
1. The role of molecular breast imaging in predicting complete tumor response to treatment and residual tumor extent following neoadjuvant therapy.
Nuvoli S; Galassi S; Gelo I; Rocchitta G; Fancellu A; Serra PA; Madeddu G; Spanu A
Oncol Rep; 2018 May; 39(5):2055-2062. PubMed ID: 29512735
[TBL] [Abstract][Full Text] [Related]
2. Assessment of Residual Disease With Molecular Breast Imaging in Patients Undergoing Neoadjuvant Therapy: Association With Molecular Subtypes.
Menes TS; Golan O; Vainer G; Lerman H; Schneebaum S; Klausner J; Even-Sapir E
Clin Breast Cancer; 2016 Oct; 16(5):389-395. PubMed ID: 27282845
[TBL] [Abstract][Full Text] [Related]
3. Comparison of
Hunt KN; Conners AL; Goetz MP; O'Connor MK; Suman V; Kalari K; Weinshilboum R; Wang L; Carter J; McLaughlin S; Aspitia AM; Gray R; Northfelt D; Boughey JC
AJR Am J Roentgenol; 2019 Oct; 213(4):932-943. PubMed ID: 31166752
[No Abstract] [Full Text] [Related]
4. Dedicated breast PET for detecting residual disease after neoadjuvant chemotherapy in operable breast cancer: A prospective cohort study.
Sasada S; Masumoto N; Goda N; Kajitani K; Emi A; Kadoya T; Okada M
Eur J Surg Oncol; 2018 Apr; 44(4):444-448. PubMed ID: 29396328
[TBL] [Abstract][Full Text] [Related]
5. Residual Mammographic Microcalcifications and Enhancing Lesions on MRI After Neoadjuvant Systemic Chemotherapy for Locally Advanced Breast Cancer: Correlation with Histopathologic Residual Tumor Size.
Kim YS; Chang JM; Moon HG; Lee J; Shin SU; Moon WK
Ann Surg Oncol; 2016 Apr; 23(4):1135-42. PubMed ID: 26628432
[TBL] [Abstract][Full Text] [Related]
6. 99mTc-sestamibi using a direct conversion molecular breast imaging system to assess tumor response to neoadjuvant chemotherapy in women with locally advanced breast cancer.
Mitchell D; Hruska CB; Boughey JC; Wahner-Roedler DL; Jones KN; Tortorelli C; Conners AL; O'Connor MK
Clin Nucl Med; 2013 Dec; 38(12):949-56. PubMed ID: 24152645
[TBL] [Abstract][Full Text] [Related]
7. Accuracy of MRI for estimating residual tumor size after neoadjuvant chemotherapy in locally advanced breast cancer: relation to response patterns on MRI.
Kim HJ; Im YH; Han BK; Choi N; Lee J; Kim JH; Choi YL; Ahn JS; Nam SJ; Park YS; Choe YH; Ko YH; Yang JH
Acta Oncol; 2007; 46(7):996-1003. PubMed ID: 17851879
[TBL] [Abstract][Full Text] [Related]
8. Accuracy of clinical examination, digital mammogram, ultrasound, and MRI in determining postneoadjuvant pathologic tumor response in operable breast cancer patients.
Croshaw R; Shapiro-Wright H; Svensson E; Erb K; Julian T
Ann Surg Oncol; 2011 Oct; 18(11):3160-3. PubMed ID: 21947594
[TBL] [Abstract][Full Text] [Related]
9. Accuracy of digital mammography, ultrasound and MRI in predicting the pathological complete response and residual tumor size of breast cancer after completion of neoadjuvant chemotherapy.
Sudhir R; Koppula VC; Rao TS; Sannapareddy K; Rajappa SJ; Murthy SS
Indian J Cancer; 2022; 59(3):345-353. PubMed ID: 33753611
[TBL] [Abstract][Full Text] [Related]
10. Role of diffusion-weighted imaging as an adjunct to contrast-enhanced breast MRI in evaluating residual breast cancer following neoadjuvant chemotherapy.
Hahn SY; Ko EY; Han BK; Shin JH; Ko ES
Eur J Radiol; 2014 Feb; 83(2):283-8. PubMed ID: 24315957
[TBL] [Abstract][Full Text] [Related]
11. Residual microcalcifications after neoadjuvant chemotherapy for locally advanced breast cancer: comparison of the accuracies of mammography and MRI in predicting pathological residual tumor.
An YY; Kim SH; Kang BJ
World J Surg Oncol; 2017 Nov; 15(1):198. PubMed ID: 29110671
[TBL] [Abstract][Full Text] [Related]
12. The use of molecular breast imaging to assess response in women undergoing neoadjuvant therapy for breast cancer: a pilot study.
Wahner-Roedler DL; Boughey JC; Hruska CB; Chen B; Rhodes DJ; Tortorelli CL; Maxwell RW; Cha SS; O'Connor MK
Clin Nucl Med; 2012 Apr; 37(4):344-50. PubMed ID: 22391702
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic performance of breast-specific gamma imaging in the assessment of residual tumor after neoadjuvant chemotherapy in breast cancer patients.
Lee HS; Ko BS; Ahn SH; Son BH; Lee JW; Kim HJ; Yu JH; Kim SB; Jung KH; Ahn JH; Cha JH; Kim HH; Lee HJ; Song IH; Gong G; Park SH; Lee JJ; Moon DH
Breast Cancer Res Treat; 2014 May; 145(1):91-100. PubMed ID: 24671359
[TBL] [Abstract][Full Text] [Related]
14. ICG fluorescence imaging as a new tool for optimization of pathological evaluation in breast cancer tumors after neoadjuvant chemotherapy.
Veys I; Pop CF; Barbieux R; Moreau M; Noterman D; De Neubourg F; Nogaret JM; Liberale G; Larsimont D; Bourgeois P
PLoS One; 2018; 13(5):e0197857. PubMed ID: 29799849
[TBL] [Abstract][Full Text] [Related]
15. Accuracy of physical examination, ultrasonography, and mammography in predicting residual pathologic tumor size in patients treated with neoadjuvant chemotherapy.
Chagpar AB; Middleton LP; Sahin AA; Dempsey P; Buzdar AU; Mirza AN; Ames FC; Babiera GV; Feig BW; Hunt KK; Kuerer HM; Meric-Bernstam F; Ross MI; Singletary SE
Ann Surg; 2006 Feb; 243(2):257-64. PubMed ID: 16432360
[TBL] [Abstract][Full Text] [Related]
16. Magnetic resonance imaging evaluation of residual tumors in breast cancer after neoadjuvant chemotherapy: surgical implications.
Zhou J; Li G; Sheng F; Qiao P; Zhang H; Xing X
Acta Radiol; 2016 May; 57(5):529-37. PubMed ID: 26231950
[TBL] [Abstract][Full Text] [Related]
17. The assessment of breast cancer response to neoadjuvant chemotherapy: comparison of magnetic resonance imaging and 18F-fluorodeoxyglucose positron emission tomography.
Park JS; Moon WK; Lyou CY; Cho N; Kang KW; Chung JK
Acta Radiol; 2011 Feb; 52(1):21-8. PubMed ID: 21498321
[TBL] [Abstract][Full Text] [Related]
18. Can breast MRI and adjunctive Doppler ultrasound improve the accuracy of predicting pathological complete response after neoadjuvant chemotherapy?
Nakashima K; Uematsu T; Harada TL; Takahashi K; Nishimura S; Tadokoro Y; Hayashi T; Watanabe J; Sugino T; Notsu A
Breast Cancer; 2021 Sep; 28(5):1120-1130. PubMed ID: 33837896
[TBL] [Abstract][Full Text] [Related]
19. The clinical impact of molecular breast imaging in women with proven invasive breast cancer scheduled for breast-conserving surgery.
Collarino A; Valdés Olmos RA; van Berkel LGAJ; Neijenhuis PA; Wijers LMH; Smit F; de Geus-Oei LF; Pereira Arias-Bouda LM
Breast Cancer Res Treat; 2018 Jun; 169(3):513-522. PubMed ID: 29435855
[TBL] [Abstract][Full Text] [Related]
20. MRI evaluation of residual breast cancer after neoadjuvant chemotherapy: influence of patient, tumor and chemotherapy characteristics on the correlation with pathological response.
Diguisto C; Ouldamer L; Arbion F; Vildé A; Body G
Anticancer Res; 2015 Jan; 35(1):581-5. PubMed ID: 25550606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
